According to our results, it is speculated that the gut microbiome changes affect the metabolism of glycerophospholipids in the body, thereby altering the expression of immune-related cytokines IFN-γ and IL-2 in the tumor microenvironment, resulting in a different therapeutic effect of PD-1 antibody. The gene discussed is IFNG; the disease is neoplasm.